Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934699 | 0.93 | CES2 (0.44) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL13934948 | 0.93 | CES2 (0.44) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL13934353 | 0.93 | CES2 (0.44) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL5367731 | 0.85 | CES2 (0.55) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9617945 | 0.85 | CES2 (0.55) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL12855284 | 0.84 | SLC7A5 (0.46) | CES2CES1 | |
| SCHEMBL29283929 | 0.83 | CES2 (0.53) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL30989579 | 0.83 | CES2 (0.53) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL30989581 | 0.83 | CES2 (0.53) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL14396400 | 0.80 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | HRH3, HRH2, HRH1 | CES2 999/4885MEN1 498/4885FAAH 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.